Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages
1 Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown 26505; 2 Department of Physiology, West Virginia University School of Medicine, Morgantown, West Virginia 26506; and 3 Department of Pediatrics, Medical University of South Carolina, Charleston...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Lung cellular and molecular physiology 1999-01, Vol.276 (1), p.186-L196 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Health Effects Laboratory
Division, National Institute for Occupational Safety and Health,
Morgantown 26505; 2 Department of
Physiology, West Virginia University School of Medicine, Morgantown,
West Virginia 26506; and
3 Department of Pediatrics,
Medical University of South Carolina, Charleston, South Carolina
29425-3313
The objectives of
this investigation were 1 ) to report
that pulmonary surfactant inhibits lipopolysaccharide (LPS)-induced nitric oxide (· NO) production by rat alveolar macrophages,
2 ) to study possible mechanisms for
this effect, and 3 ) to determine which surfactant component(s) is responsible. · NO produced
by the cells in response to LPS is due to an inducible · NO
synthase (iNOS). Surfactant inhibits LPS-induced · NO
formation in a concentration-dependent manner; · NO
production is inhibited by ~50 and ~75% at surfactant levels
of 100 and 200 µg phospholipid/ml, respectively. The inhibition is
not due to surfactant interference with the interaction of LPS with the
cells or to disruption of the formation of iNOS mRNA. Also, surfactant
does not seem to reduce · NO formation by directly affecting
iNOS activity or by acting as an antioxidant or radical scavenger.
However, in the presence of surfactant, there is an ~80% reduction
in the amount of LPS-induced iNOS protein in the cells. LPS-induced
· NO production is inhibited by Survanta, a surfactant
preparation used in replacement therapy, as well as by natural
surfactant. · NO formation is not affected by the major lipid
components of surfactant or by two surfactant-associated proteins,
surfactant protein (SP) A or SP-C. However, the hydrophobic SP-B
inhibits · NO formation in a concentration-dependent manner; · NO production is inhibited by ~50 and ~90% at SP-B
levels of 1-2 and 10 µg/ml, respectively. These results show
that lung surfactant inhibits LPS-induced · NO production by
alveolar macrophages, that the effect is due to a reduction in iNOS
protein levels, and that the surfactant component responsible for the
reduction is SP-B.
lipopolysaccharide; surfactant protein B; hydrophobic surfactant
proteins; inducible nitric oxide synthase |
---|---|
ISSN: | 1040-0605 0002-9513 1522-1504 |
DOI: | 10.1152/ajplung.1999.276.1.l186 |